© 1988 Oxford University Press
research-article |
Carcinogenicity Study of Auranofin, an Orally Administered Gold Compound, in Mice



,1
*Hazleton Laboratories America Inc. 9200 Leesburg Turnpike, Vienna, Virginia 22180.
Pathology and Toxicology Department, Smith Kline & French Laboratories 709 Swede/and Road, King of Prussia, Pennsylvania 19406.
PRL, P.O. Box 1002, Alexandria, Virginia 22313
Received October 28, 1987; accepted February 8, 1988
Carcinogenicity Study of Auranofin, an Orally Administered Gold Compound, in Mice. Markiewicz, V. R., Saunders, L. Z., Geus, R. J., Payne, B. J. and Hook, J. B. (1988). Fundam Appl Toxicol. 11, 277284. Auranofin, a gold-containing compound, was administered to Charles River CO-1 mice for 18 months to assess its possible carcinogenicity. The mice were dosed orally with 1.0,3.0, or 6.0 (increased to 9.0 on Day 294) mg/kg/day. Each dose group and each of two control groups contained 110 males and 110 females. Survival was greater than 70% at the end of the study. No effect of the treatment on neoplastic or nonneoplastic lesions was found. This is in contrast to the results reported in rats. Auranofin in rats produced a heavy metal nephropathy characterized by acute coagulative necrosis, subacute renal cortical fibrosis, chronic cytomegaly and karyomegaly, and finally renal cortical neoplasia (adenomas and adeno-carcinomas). The lack of effect of auranofin on tumor incidence in mice suggests the findings in rats may be Species specific.